Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
Y2TV3uaGCttRnrJ0
Listen
